Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PMID: 39083703

Abstract

PURPOSE: Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular profiling, which is not universally available.

Authors

  • Erik N Bergstrom
    Moores Cancer Center, UC San Diego, La Jolla, CA.
  • Ammal Abbasi
    Moores Cancer Center, UC San Diego, La Jolla, CA.
  • Marcos Díaz-Gay
    Moores Cancer Center, UC San Diego, La Jolla, CA.
  • Loïck Galland
    Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
  • Sylvain Ladoire
    Centre Georges François Leclerc, Dijon, France.
  • Scott M Lippman
    Department of Thoracic-Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ludmil B Alexandrov
    Theoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.

Keywords

External Resources

Popular Topics
Recent Journals